Ana amfani da Injections Euflexxa a Viscosupplementation
Euflexxa wani bayani ne na hyaluronan mai tsabta (wanda ake kira hyaluronic acid ko sodium hyaluronate) a saline. A hyaluronan a Euflexxa an samo daga kwayoyin Kwayoyin cuta. Shi ne farkon wanda bai samo hyaluronan ba.
Euflexxa yana daya daga cikin hyaluronates da aka yi amfani da shi a viscosuplationation . Euflexxa an yi shige ta kai tsaye a cikin mahadar gwiwa domin sake mayar da kayan haɓaka da kuma lubricating na ruwa na yau da kullum (watau haɗin gwiwa).
Abun dajin da ke dauke da maganin ƙwayar wariyar launin fata sun rasa dukiyar su.
Bayyanawa ga Euflexxa
Edinlexxa ya amince da ita a ranar 3 ga watan Disamba, 2004 don maganin ciwon gwiwoyin gwiwa tare da osteoarthritis a cikin marasa lafiya wadanda basu kasa amsa maganin magungunan marasa magani ba (misali, farfadowa na jiki) da kuma maganin analgesics mai sauki, irin su acetaminophen . Euflexxa an gudanar da shi azaman jerin nau'in injections na cikin mako uku.
Contraindications ga Euflexxa
Mutanen da ke da sanannun sanannun kayayyakin hyaluronan ba za a bi da su tare da Euflexxa ba. Har ila yau, mutanen da ke fama da kamuwa da cuta a cikin gwiwa gwiwa, wasu kamuwa da cuta, ko cutar fata a yankin da inuwa zai faru ba kamata a bi da shi tare da Euflexxa.
Hanyoyin Kayan Kasuwanci da abubuwan da ke faruwa
Abubuwa mafi banbanci wadanda suka hada da cutar Euflexxa a yayin nazarin asibiti sun hada da arthralgia (ciwon haɗin gwiwa), ciwo mai zafi, ciwo a cikin makamai ko ƙafafu, zafi na musculoskeletal, da kuma haɗuwa da haɗin gwiwa.
Abubuwa masu ban mamaki da zasu iya faruwa tare da duk wani allurar rigakafi na ciki sun hada da arthralgia, haɗuwa da haɗin gwiwa, haɗin gwiwa, ciwon gurasar injin, da kuma ciwon maganin.
Tsanani da gargadi
Bayan sun karbi magungunan ƙwayar cutar ta Euflexxa, kamar yadda aka yi da allurar haɗin gwiwa, an bada shawara cewa mai yin haƙuri ya kauce wa ayyukan da ya dace ko ayyukan tsagewa tsawon tsawon sa'o'i 48.
Har ila yau, ya kamata a lura cewa ciwo ko kumburi zai iya faruwa bayan inji, amma zai rage bayan an gajeren lokaci.
Tsaro da tasiri na Euflexxa ba a kafa su cikin mata masu juna biyu ba. Ba a sani ba idan an cire Euflexxa a madarar mutum kamar yadda ya kamata ba a tabbatar da tasiri a cikin lactating mata. Har ila yau, rashin lafiya da tasiri na Euflexxa ba a kafa a cikin yara ba.
Layin Ƙasa
Sauran takardun izini na FDA, tare da ranar da aka amince su, sun haɗa da:
- Hyalgan 05/28/1997
- Synvisc 08/08/1997
- Supartz 01/24/2001
- Orthovisc 02/05/2004
Ƙungiyar Amurka na Orthopedic Surgeons (AAOS) ta kammala, "Ko da yake wasu marasa lafiya sun ba da labari game da bayyanar cututtukan cututtuka da maganin ƙwayar cutar, ba a nuna cewa hanya ba ta sake juya tsarin maganin arthritic ko sake karamin guringuntsi.Idan tasirin viscosuplation a maganin arthritis ba a bayyana ba An ba da shawara cewa yin amfani da maganin yafi dacewa idan arthritis ya kasance a farkon matakan (m zuwa matsakaici), amma ana bukatar karin bincike don tallafawa wannan.
> Sources:
> Magungunan Viscosupplementation na Knee Arthritis. OrthoInfo (AAOS). Binciken Yuni na 2015.
> Euflexxa. Bayyana Bayani. Yuli 2017
> Ferring Pharmaceuticals ta sanar da kaddamar da Euflexxa ga Osteoarthritis Knee Pain, News Release Ferring Pharmaceuticals Inc., Nuwamba 14, 2005.